Stay updated on Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial.
Sign up to get notified when there's something new on the Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial. page.

Latest updates to the Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial. page
- CheckyesterdayNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page now displays Revision: v3.3.2, replacing Revision: v3.3.1.SummaryDifference0.0%

- Check23 days agoChange DetectedPublication notes were added clarifying that publications may relate to the study results and are automatically filled from PubMed. The page revision was updated to v3.3.1.SummaryDifference0.3%

- Check30 days agoChange DetectedThe study location list now includes Tainan, Taiwan, 70457 instead of Tainan City, Taiwan, 70457, and the funding-status notice was removed.SummaryDifference0.1%

- Check44 days agoChange DetectedNo significant changes detected; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check52 days agoChange DetectedAdded Cali, Valle del Cauca Department, Colombia, 760042 to the locations list and removed Santiago de Cali, Valle del Cauca Department, Colombia, 760042.SummaryDifference0.0%

- Check73 days agoChange DetectedUpdate the page to v3.2.0 with a government funding notice about potential delays and current operating status for the NIH Clinical Center; remove the old v3.1.0 reference.SummaryDifference1%

Stay in the know with updates to Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial.
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial. page.